Free Trial
NASDAQ:NERV

Minerva Neurosciences Q1 2025 Earnings Report

Minerva Neurosciences logo
$2.13 -0.04 (-1.84%)
Closing price 07/25/2025 03:59 PM Eastern
Extended Trading
$2.19 +0.06 (+2.82%)
As of 07/25/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Minerva Neurosciences EPS Results

Actual EPS
-$0.50
Consensus EPS
-$1.07
Beat/Miss
Beat by +$0.57
One Year Ago EPS
N/A

Minerva Neurosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Minerva Neurosciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Minerva Neurosciences' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled on Friday, August 1, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Minerva Neurosciences Earnings Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Minerva Neurosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Minerva Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Minerva Neurosciences and other key companies, straight to your email.

About Minerva Neurosciences

Minerva Neurosciences (NASDAQ:NERV)., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

View Minerva Neurosciences Profile

More Earnings Resources from MarketBeat